Author: admin als-handoff

SEATTLE, Wash. and VANCOUVER, British Columbia, October 1, 2018 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 1,789,258 shares…

SEATTLE, Wash and VANCOUVER, British Columbia, Sept. 27, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of a new formulation for cytisine. The study…

SEATTLE, Wash. and VANCOUVER, British Columbia, Sept. 26, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference being held Tuesday,…

Cytisine Demonstrated Superior Abstinence Rates Compared to Nicotine Replacement Therapy. SEATTLE, Wash. and VANCOUVER, British Columbia, Sept. 18, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the publication of new cytisine data from an independent observational study…

SEATTLE, Wash. and VANCOUVER, British Columbia, Sept. 6, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced that cytisine data will be presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference , September 6-8th in Munich, Germany. The presentations include a review of cytisine’s safety profile and an…